Dietary salt intake worsens the Th17-dependent inflammatory profile of patients with cirrhosis
BACKGROUNDLiver cirrhosis is characterized by chronic inflammation and fibrosis, with Th17 cells playing a crucial role in its progression. Recent evidence suggests that dietary salt influences immune diseases by modulating Th17 differentiation. This study assessed the impact of dietary salt on Th17-driven inflammation in patients with compensated cirrhosis and explored its effects on liver injury in mouse models.METHODSA nondrug, open-label, nonrandomized study involved 37 patients with compensated cirrhosis, who were given personalized guidelines to reduce salt intake over 3 months. Changes in Th17-driven inflammation and liver function markers were assessed at baseline and after salt restriction. In parallel, the impact of a high-salt diet on hepatic CD4+ T cells was analyzed in mouse models of acute liver injury and fibrosis.RESULTSHigh salt intake was associated with Th17-mediated inflammation and correlated with markers of impaired liver function in these patients. Importantly, moderating salt intake through a personalized nutritional intervention was sufficient to reduce CD4+ T cell-mediated inflammation. Furthermore, analysis of RNA-seq data revealed enrichment of salt-induced Th17 gene signatures in both liver tissue and peripheral cells from patients with liver disease. Similarly, mice fed a high salt diet showed hepatic enrichment of Th17 cells and exacerbated liver fibrosis upon injury. Mechanistic studies revealed that high sodium conditions activated NF-κB and induced IL-6 production in hepatocytes, which may promote Th17 responses.CONCLUSIONDietary salt exacerbates Th17-driven inflammation and contributes to cirrhosis progression. Salt reduction may represent a viable therapeutic approach to manage inflammation in compensated cirrhosis.FUNDINGGrants PI19/01554 and PI22/01907 from Instituto de Salud Carlos III (Madrid, Spain), CDEI-03/20-A and CIPROM/2023/4 from Generalitat Valenciana (Valencia, Spain), CNS2023-145676 from the National Research Agency (AEI) (Madrid, Spain), and LCF/BQ/D121/11860047 from La Caixa Foundation (Barcelona, Spain).
Authors
- Yin Huang (ORCID: https://orcid.org/0000-0002-6228-2360)
- José M. González‐Navajas (ORCID: https://orcid.org/0000-0002-1591-939X)
- Beatriz Lozano‐Ruiz
- Juan José Lozano (ORCID: https://orcid.org/0000-0001-7613-3908)
- Amalia Tzoumpa (ORCID: https://orcid.org/0000-0003-3733-4090)
- Pedro Zapater
- Cayetano Miralles (ORCID: https://orcid.org/0000-0003-2037-6358)
- Iván Herrera
- Alba Moratalla
- Pablo Bellot (ORCID: https://orcid.org/0000-0001-8307-1813)
- Paula Piñero (ORCID: https://orcid.org/0000-0002-4230-581X)
- Joanna Picó (ORCID: https://orcid.org/0000-0003-0909-8094)
- María Laura Pomares
- Sonia Pascual (ORCID: https://orcid.org/0000-0002-4265-5019)
- Maria M. Rodríguez (ORCID: https://orcid.org/0009-0003-3979-5250)
- Fabián Tarín
Institutions
- Universitat de Miguel Hernández d'Elx (ES)
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
Publication Details
- Journal
- JCI Insight
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1172/jci.insight.191354
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Generalitat Valenciana
- Instituto de Salud Carlos III